Now that the US has stopped funding Gavi, the vaccine alliance will likely become more dependent on philanthropy than ever before.
Articles on Merck
Displaying all articles
Sierra Leone was one of three countries ravaged by the Ebola epidemic 10 years ago. A national vaccine campaign is a big step towards preventing future outbreaks.
Both companies say their drugs will work against the Omicron variant, though this is based on preliminary, lab-based research.
Merck and Pfizer both have oral antiviral pills under review by the FDA. Such treatments could help turn the tide of the pandemic.
Paxlovid is one potential COVID drug for use at home. The idea is these can potentially be prescribed at the first sign of infection to prevent serious illness and death.
Ivermectin has been a lifesaving drug for people with parasitic infections like river blindness and strongyloidiasis. But taking it for COVID-19 may result in the opposite effect.
Merck announced preliminary data suggesting the drug reduced the risk of hospitalisation and death by 50%.
The COVID pandemic is giving drug companies an opportunity to reset their image. So how did they get so big and their credibility sink so low?
Our best shot at ending the pandemic is by achieving herd immunity through widespread use of a vaccine. But that won’t happen unless people believe it’s safe.
Trump’s reaction to the violence in Charlottesville, Virginia, prompted business leaders to sever ties with two White House councils.
New drug combination cures over 95% of cases but the cost would swallow the entire health budget. Pity the politicians that have to figure this one out.
Top contributors
-
Professor of Pharmaceutical Chemistry, Macquarie University
-
Pharmacist and PhD Candidate, University of Sydney
-
Professor of Epidemiology and Population Health, Glasgow Caledonian University
-
Researcher, Glasgow Caledonian University
-
Assistant Professor of Infectious Diseases, University of Virginia
-
Professor of Law and Public Health, The Ohio State University
-
Senior Research Manager, University of Sydney and Honorary Assistant Professor, Bond University
-
Associate Professor in Pharmacology, University of Sydney
-
Associate Professor of Pharmacy, University of Connecticut
-
Professor in the faculty of Medicine, Mbarara University of Science and Technology
-
Researcher, Glasgow Caledonian University
-
Professor of Cultural Anthropology and International Studies, University of Wisconsin-Madison
-
Senior Lecturer in Managerial Communication, MIT Sloan School of Management